Exhibit 99.1 FOR IMMEDIATE RELEASE Compugen Reports Fourth Quarter and Full Year 2024 Results In January and February 2025, subsequent to the financial results for the year ended December 31, 2024, a total of approximately 3.96 million shares were sold through the Company's ATM facility contributing net proceeds of approximately $8.87 million (net of $274 thousand commission issuance expenses). Compugen expects that its current cash will be sufficient to fund its operating plans into 2027. The Company has n ...

Core Viewpoint - Compugen Ltd. is positioned for growth in 2025, supported by a diverse pipeline and significant clinical advancements made in 2024, particularly with COM701 and partnerships with AstraZeneca and Gilead [2][3]. Financial Highlights - As of December 31, 2024, Compugen reported approximately $103.3 million in cash and equivalents, including a $60 million upfront payment from Gilead and milestone payments from AstraZeneca [5][8]. - Revenues for Q4 2024 were approximately $1.5 million, with total revenues for the year at $27.9 million, a decrease from $33.5 million in 2023 [9]. - The company reported a net loss of approximately $6.1 million for Q4 2024 and a net loss of approximately $14.2 million for the full year, compared to a net income of $9.7 million in Q4 2023 [13]. Clinical Developments - Compugen is on track to initiate a randomized adaptive platform trial for COM701 in Q2 2025, targeting maintenance therapy for patients with platinum-sensitive ovarian cancer [6][7]. - The first patient was dosed in Q1 2025 for the Phase 1 trial of GS-0321, a potential first-in-class anti-IL18BP antibody licensed to Gilead [6]. - AstraZeneca is conducting seven Phase 3 trials for rilvegostomig, a bispecific antibody derived from Compugen's COM902, with early data expected in 2025 [2][6]. Research and Development - R&D expenses for 2024 decreased to approximately $24.8 million from $34.5 million in 2023, primarily due to reclassification of expenses related to GS-0321 [11]. - The company continues to leverage its AI/ML-powered predictive computational discovery platform, UnigenTM, to support its early pipeline [3]. Future Milestones - Key upcoming milestones include the initiation of the COM701 trial in Q2 2025 and the expected data release from AstraZeneca regarding rilvegostomig in 2025 [7].

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that specializes in computational target discovery [1][3] - The company will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025 [1][2] Company Overview - Compugen utilizes its predictive computational discovery platform, Unigen™, to identify new drug targets and biological pathways for cancer immunotherapies [3] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3] - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3] - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]

Core Insights - Compugen Ltd. announced a collaboration with Ultima Genomics to enhance its gene sequencing database through the integration of AI/ML powered predictive computational discovery platform, Unigen, and high throughput single cell sequencing technology [1][2] - The collaboration aims to uncover new insights into gene structure for immuno-oncology, with findings presented at the AGBT conference [2][3] - Compugen plans to leverage Ultima's technology to develop proprietary single cell atlases for accelerated discovery of new immunotherapies [2] Group 1: Collaboration and Technology - Compugen's Chief Scientific Officer highlighted the development of algorithms to study gene splicing at single cell resolution, analyzing patient tumor samples to identify potential regulatory mechanisms in immuno-oncology [2] - Ultima Genomics' UG 100 sequencing platform is designed to provide lower cost sequencing and more omics data, facilitating new applications and insights in cancer research [2][6] - The collaboration is expected to transform data-starved applications in immuno-oncology through large-scale data and AI/ML techniques [2] Group 2: Research Findings - A poster presented at the AGBT 2025 meeting detailed the use of 3' single cell sequencing to study patient-derived tumor cells, revealing enhanced potential to study differential splicing at the cell type level [3] - Comparative analysis using tumor samples showed high consistency in single-cell expression levels across Ultima's UG 100 and Illumina's Novaseq 6000 sequencing platforms, with UG 100 providing clearer demarcation of 3' mRNA transcript ends [6] - The gene structure information identified through this approach contributes to the predictive models of Unigen, enhancing the understanding of tumor biology and immune regulation [5][6] Group 3: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company focused on identifying new drug targets and biological pathways for cancer immunotherapies [8] - The company has two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a collaboration with AstraZeneca [8] - Compugen's Unigen platform integrates various biological data, including multi-omics and single-cell RNA sequencing, to discover novel drug targets and understand complex biology [7]

Core Viewpoint - Compugen Ltd. is set to release its fourth quarter and full year 2024 financial results on March 4, 2025, before U.S. markets open, followed by a conference call for a corporate update [1]. Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes its predictive computational discovery platform, Unigen™, to identify new drug targets and biological pathways for cancer treatment [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3]. - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs addressing various immune resistance mechanisms [3]. - The company is headquartered in Israel with offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3].

Group 1 - Compugen is an under-the-radar player in the biotech industry, focusing on computationally driven drug discovery [1] - The company targets less-known immune pathways such as PVRIG and IL-18 binding protein, differentiating itself from big pharma's focus on familiar checkpoint inhibitors [1] - Compugen is positioned in a sector poised for exponential expansion, indicating potential for high growth [1]

Core Viewpoint - Compugen Ltd. has initiated a Phase 1 clinical trial for COM503, a potential first-in-class antibody targeting IL-18 binding protein, licensed to Gilead, marking a significant advancement in cancer immunotherapy [1][7]. Group 1: Clinical Trial Details - The Phase 1 trial is a multi-center dose escalation and expansion study aimed at evaluating the safety, tolerability, and pharmacokinetics of COM503 both as a monotherapy and in combination with Gilead's anti-PD1 antibody, zimberelimab, in patients with advanced solid tumors [2][4]. - The trial commenced in the fourth quarter of 2024 as planned, with the primary objectives including assessing safety and identifying the maximum tolerated dose [4]. Group 2: Mechanism of Action - COM503 is designed to block the endogenous IL-18 binding protein, which inhibits the anti-tumor activity of IL-18, thereby potentially enhancing local immune responses against tumors [3][5]. - The unique mechanism of action of COM503 offers a novel treatment option for cancer patients, as noted by clinical researchers involved in the trial [3]. Group 3: Licensing Agreement and Financials - In December 2023, Compugen and Gilead entered into a licensing agreement granting Gilead exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including COM503 [5]. - Compugen received an upfront payment of $60 million and an additional $30 million upon IND clearance, with potential future milestone payments totaling up to $758 million, leading to a total deal value of up to $848 million [5]. Group 4: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery platform, Unigen™, to identify new drug targets for cancer immunotherapies [6][8]. - The company has two other proprietary product candidates in Phase 1 development, COM701 and COM902, targeting different mechanisms in solid tumors [6].

Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer Further strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitors HOLON, Israel, Nov. 27, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program Yvonne Naughton - Head of IR and Corporate Communications Conference Call Participants ...

Compugen (CGEN) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this drug developer would post a loss of $0.08 per share when it actually produced a loss of $0.02, delivering a surprise of 75%. Over the last four quarters, the company has surpa ...